中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

ESMO Breast Cancer：New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group, today annouces that, the ...

2023-05-11
Simcere Zaiming will Present 8 Research Abstracts at the 2023 AACR Annual Meeting

April 10 2023 Simcere Zaiming (Company), a pharmaceutical company focused on developing drugs to address unmet clinical needs for cancer patient...

2023-04-19
Simcere Zaiming Doses First Patient in Phase 1 Trial of SIM0348, a TIGIT/PVRIG Bi-specific Antibody

On April 03, 2023, Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group, (the “C...

2023-04-03
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

NANJING, CHINA / March 14, 2023 — Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announc...

2023-03-14
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.